



# MARKET RELEASE

9 April 2018

**Phylogica Limited**

## **TRADING HALT**

The securities of Phylogica Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday 11 April 2018 or when the announcement is released to the market.

Security Code:           PYC

Anjuli Sinniah

**SENIOR ADVISER, LISTINGS COMPLIANCE (PERTH)**

## Request for Trading Halt

**9 April 2018**

In accordance with Listing Rule 17.1, Phylogica Limited requests that an immediate trading halt be placed on its securities pending an update to the market on the Board and Management of the Company.

The Company anticipates that the trading halt will be lifted on or before market open on Wednesday, 11 April 2018 by provision of an announcement to ASX regarding this matter.

The Company is not aware of any reason why the trading halt should not be granted, nor of any other information relevant to this request

Yours faithfully

A handwritten signature in black ink, appearing to read 'Kevin Hart', with a stylized flourish extending to the right.

Kevin Hart

**Company Secretary**

**ENDS**

## About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company's lead asset program has identified a phylomer which can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has had collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and is currently working with Genentech.

---

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

[www.phylogica.com](http://www.phylogica.com)

**Phylogica Ltd**

ABN 48 098 391 961